Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Source: View publication →
In intermediate-risk patients with severe symptomatic aortic stenosis, transcatheter aortic-valve replacement (TAVR) with a self-expanding prosthesis was noninferior to surgical aortic-valve replacement (SAVR) for the composite endpoint of all-cause mortality or disabling stroke at 24 months.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SURTAVI trial cemented TAVR as a safe, efficacious, and noninferior alternative to SAVR in intermediate-risk patients with severe aortic stenosis. By proving that self-expanding platforms provide excellent survival and superior hemodynamics—despite trade-offs regarding pacemaker implantation and paravalvular leak—it catalyzed a paradigm shift that formally expanded TAVR indications from high-risk/inoperable patients to the broader intermediate-risk population, ultimately paving the way for subsequent trials in low-risk cohorts.
Historical Context
Prior to SURTAVI, landmark trials (PARTNER 1, CoreValve High Risk Pivotal) had already established TAVR as the standard of care for extreme- and high-risk surgical patients. Concurrently, the PARTNER 2A trial demonstrated the noninferiority of a balloon-expandable TAVR system in intermediate-risk patients. SURTAVI corroborated these findings using a self-expanding platform, solidifying a device 'class effect' regarding TAVR noninferiority in intermediate-risk populations and accelerating the therapy's expansion into lower-risk groups.
Guided Discussion
High-yield insights from every perspective
What is the classic clinical triad of severe aortic stenosis, and pathophysiologically, why does replacing the valve (via TAVR or SAVR) dramatically improve survival compared to medical management?
Key Response
The classic triad consists of angina, syncope, and heart failure (exertional dyspnea). Aortic stenosis causes a fixed mechanical outflow obstruction, leading to increased left ventricular afterload, compensatory concentric hypertrophy, and eventual decompensation. Because the obstruction is purely mechanical, pharmacological therapies cannot reverse it; valve replacement is the only definitive intervention to restore normal hemodynamics and prevent mortality.
Based on the SURTAVI findings, what are the most common periprocedural complications associated with TAVR versus SAVR that you should discuss with an intermediate-risk patient during the informed consent process?
Key Response
Residents must counsel patients on differing risk profiles: TAVR with a self-expanding valve is associated with higher rates of permanent pacemaker implantation and residual paravalvular regurgitation. Conversely, SAVR is associated with higher rates of acute kidney injury, new-onset atrial fibrillation, and bleeding requiring transfusions. Understanding these tradeoffs is essential for shared decision-making.
How does the self-expanding mechanism of the CoreValve/Evolut R used in SURTAVI anatomically influence the conduction system compared to balloon-expandable valves, and how does this affect patient selection in someone with a pre-existing right bundle branch block (RBBB)?
Key Response
Self-expanding valves typically have a deeper implantation depth into the left ventricular outflow tract (LVOT) and exert continuous radial outward force, causing mechanical pressure on the His bundle and left bundle branch. In a patient with pre-existing RBBB, this significantly increases the risk of complete heart block and permanent pacemaker requirement, which might favor the selection of a balloon-expandable valve or SAVR to minimize pacing-induced cardiomyopathy risk.
Since TAVR proved noninferior to SAVR for mid-term mortality and stroke in intermediate-risk patients, how should the persistent risks of permanent pacemakers and mild paravalvular leak influence our long-term management strategy for younger, more active patients?
Key Response
Attendings must balance procedural safety with lifelong consequences. Right ventricular pacing and even mild paravalvular leak can progressively impair left ventricular function and lead to heart failure over a 10-15 year horizon. In younger intermediate-risk patients, the immediate appeal of a less invasive TAVR must be weighed against the unknown long-term durability of the prosthesis and the compounding hemodynamic effects of these periprocedural complications.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SURTAVI trial utilized a Bayesian statistical design to evaluate noninferiority. What are the methodological implications of incorporating informative priors from earlier high-risk trials into this intermediate-risk population, and how might this affect the type I error rate?
Key Response
A Bayesian design allows for smaller sample sizes and adaptive interim analyses by 'borrowing strength' from prior data (e.g., CoreValve High Risk trial). However, if the physiological response or event rates in the intermediate-risk population differ fundamentally from the high-risk priors, it could inappropriately bias the posterior probability toward noninferiority, potentially inflating the type I error if the prior distribution is not adequately discounted.
During the SURTAVI trial, the protocol was amended to allow the use of the newer-generation Evolut R device alongside the first-generation CoreValve. As a peer reviewer, how does this intra-trial device iteration threaten the internal validity of the study and the interpretability of its composite endpoint?
Key Response
Introducing a newer device mid-trial is a major methodological challenge. The Evolut R has a lower profile and allows repositionability, potentially lowering pacemaker and leak rates compared to the original CoreValve. Pooling these devices complicates safety and efficacy analyses, introducing chronological bias and making it difficult to determine whether noninferiority is driven by the intrinsic benefits of TAVR or by the performance enhancements of the newer iteration alone.
Given the noninferiority data from SURTAVI (self-expanding) and PARTNER 2 (balloon-expandable), how should current ACC/AHA valvular heart disease guidelines shift from surgical risk-based algorithms to age- and anatomy-based algorithms for managing severe aortic stenosis?
Key Response
Because intermediate and low-risk trials proved TAVR is a viable alternative to SAVR across risk strata, modern guidelines must de-emphasize STS risk scores as the sole decider. Current guidelines (e.g., 2020 ACC/AHA) now emphasize age (Class I for SAVR in patients <65 due to durability, Class I for TAVR in patients >80) and life expectancy, reflecting that the presence of bicuspid anatomy, vascular access issues, or multi-vessel CAD now play a much larger role in determining the optimal intervention than baseline surgical risk alone.
Clinical Landscape
Noteworthy Related Trials
PARTNER 2A Trial
Tested
TAVR with SAPIEN XT valve
Population
Patients with severe aortic stenosis at intermediate surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Death from any cause or disabling stroke at 2 years
PARTNER 3 Trial
Tested
TAVR with SAPIEN 3 valve
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Composite of death, stroke, or rehospitalization at 1 year
Evolut Low Risk Trial
Tested
TAVR with self-expanding valves (CoreValve, Evolut R, or Evolut PRO)
Population
Patients with severe aortic stenosis at low surgical risk
Comparator
Surgical Aortic-Valve Replacement (SAVR)
Endpoint
Death or disabling stroke at 24 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis